echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Junshi Bio-Toripalimab combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma was approved by the State Drug Administration

    Junshi Bio-Toripalimab combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma was approved by the State Drug Administration

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    SHANGHAI, May 16, 2022 /PRNewswire/ -- On May 16, 2022, Junshi Bio announced that the company's self-developed anti-PD-1 monoclonal antibody Toripalimab Injection (Tuoyi® ) in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC) was approved by the National Medical Products Administration (NMP.


    Esophageal cancer is one of the most common malignant tumors in the digestive tra.


    The approval of this new indication is mainly based on data from a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial JUPITER-06 (NCT0382996


    The research results of JUPITER-06 were published in Cancer Cell, a top international oncology journal (impact factor: 374


    Professor Xu Ruihua, principal investigator of JUPITER-06 and Sun Yat-Sen University Cancer Center, said: "China is one of the countries with a high incidence of esophageal cancer, but due to the different etiology and pathological characteristics of patients in the East and the West, the main subtypes of esophageal squamous cell carcinoma in China are develop.


    In overseas markets, Toripalimab has been granted Orphan-drug Designation by the.


    "The onset of esophageal cancer is insidious, and many patients are in the advanced stage when they are first diagnos.


    .


    About Toripalimab Injection (Tuoyi®)

    Toripalimab injection (Tuoyi®), as the first domestically produced monoclonal antibody targeting PD-1 approved for marketing in China, has been supported by major national science and technology projects and won the highest award in the national patent field "China Patent Gold Awar.


    In March 2021, toripalimab was included in the Breakthrough Therapy Drug Program by the NMPA for the first-line treatment of advanced mucosal melano.


    Toripalimab started clinical research and development in early 201 So far, more than 30 clinical studies covering more than 15 indications have been carried out around the wor.


    [1] https://g.


    [2] https://g.


    [3] Abnet, CC, Arnold,.


    [4] Wang et .


    Source: Junshi Biotechnology

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.